Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease

Cytotherapy

Volumn 17, Issue 7, 2015, Pages 948-955

  Arbez, Jessy ^a,b,c   Saas, Philippe ^a,b,c   Lamarthée, Baptiste ^a,b,c   Malard, Florent ^d,e   Couturier, Mélanie ^a,b,c   Mohty, Mohamad ^f,g   Gaugler, Béatrice ^a,b,c  

^a RIGHT Interactions Hôte Greffon Tumeur Ingénierie Cellulaire et Génique   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e Team 12   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

Acute GVHD; Dendritic cells; Immune effectors; Mobilization; Peripheral blood stem cells; Plerixafor

Indexed keywords

ATAXIN 1; CHEMOKINE RECEPTOR CCR6; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; CCR6 PROTEIN, MOUSE; GRANULOCYTE COLONY STIMULATING FACTOR; HETEROCYCLIC COMPOUND; LY ANTIGEN; LY6A PROTEIN, MOUSE; MEMBRANE PROTEIN; STEM CELL FACTOR RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; GRAFT FAILURE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMOBILIZED CELL; IN VIVO STUDY; MORTALITY; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; UPREGULATION; ANIMAL; C57BL MOUSE; CYTOLOGY; DENDRITIC CELL; GRAFT VS HOST DISEASE; IMMUNOLOGY; METABOLISM; PROCEDURES; SPLEEN; STEM CELL MOBILIZATION;

ANIMALS; ANTIGENS, LY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, CCR6; SPLEEN;

EID: 84946488020     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.02.009     Document Type: Article

References (29)

1. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 2006, 354:1813-1826.
2. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
3. Liles W.C., Broxmeyer H.E., Rodger E., Wood B., Hubel K., Cooper S., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
4. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
5. Liles W.C., Rodger E., Broxmeyer H.E., Dehner C., Badel K., Calandra G., et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
6. Malard F., Kroger N., Gabriel I.H., Hubel K., Apperley J.F., Basak G.W., et al. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012, 18:314-317.
7. Mohty M., Duarte R.F., Croockewit S., Hubel K., Kvalheim G., Russell N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 2011, 25:1-6.
8. Morris E.S., MacDonald K.P., Rowe V., Johnson D.H., Banovic T., Clouston A.D., et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood 2004, 103:3573-3581.
9. Hill G.R., Olver S.D., Kuns R.D., Varelias A., Raffelt N.C., Don A.L., et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 2010, 116:819-828.
10. Morris E.S., MacDonald K.P., Hill G.R. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. Blood 2006, 107:3430-3435.
11. Holtan S.G., Porrata L.F., Micallef I.N., Padley D.J., Inwards D.J., Ansell S.A., et al. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2007, 7:315-318.
12. Varmavuo V., Mantymaa P., Nousiainen T., Valonen P., Kuittinen T., Jantunen E. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol 2012, 89:128-135.
13. Gaugler B., Arbez J., Legouill S., Tiberghien P., Moreau P., Derenne S., et al. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy 2013, 15:861-868.
14. Devine S.M., Vij R., Rettig M., Todt L., McGlauchlen K., Fisher N., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
15. Couturier M., Lamarthee B., Arbez J., Renauld J.C., Bossard C., Malard F., et al. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect. Leukemia 2013, 27:1527-1537.
16. Banovic T., Markey K.A., Kuns R.D., Olver S.D., Raffelt N.C., Don A.L., et al. Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells. J Immunol 2009, 182:912-920.
17. Kean L.S., Sen S., Onabajo O., Singh K., Robertson J., Stempora L., et al. Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood 2011, 118:6580-6590.
18. He S., Chu J., Vasu S., Deng Y., Yuan S., Zhang J., et al. FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome. Biol Blood Marrow Transplant 2014, 20:309-313.
19. Kunkel E.J., Butcher E.C. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002, 16:1-4.
20. Varona R., Cadenas V., Gomez L., Martinez A.C., Marquez G. CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood 2005, 106:18-26.
21. Varona R., Cadenas V., Lozano M., Moreno-Ortiz M.C., Kremer L., Martinez A.C., et al. CCR6 regulates the function of alloreactive and regulatory CD4+ T cells during acute graft-versus-host disease. Leuk Lymphoma 2006, 47:1469-1476.
22. Kappel L.W., Goldberg G.L., King C.G., Suh D.Y., Smith O.M., Ligh C., et al. IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 2009, 113:945-952.
23. Yu Y., Wang D., Liu C., Kaosaard K., Semple K., Anasetti C., et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORgammat in mice. Blood 2011, 118:5011-5020.
24. Bossard C., Malard F., Arbez J., Chevallier P., Guillaume T., Delaunay J., et al. Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. Leukemia 2012, 26:1471-1474.
25. Kang Y., Chen B.J., Deoliveira D., Mito J., Chao N.J. Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS One 2010, 5:e11316.
26. MacDonald K.P., Le Texier L., Zhang P., Morris H., Kuns R.D., Lineburg K.E., et al. Modification of T cell responses by stem cell mobilization requires direct signaling of the T cell by G-CSF and IL-10. J Immunol 2014, 192:3180-3189.
27. Arpinati M., Green C.L., Heimfeld S., Heuser J.E., Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000, 95:2484-2490.
28. MacDonald K.P., Rowe V., Filippich C., Thomas R., Clouston A.D., Welply J.K., et al. Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. Blood 2003, 101:2033-2042.
29. Waller E.K., Logan B.R., Harris W.A., Devine S.M., Porter D.L., Mineishi S., et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naive T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol 2014, 32:2365-2372.